ATEC vs XTNT vs NVCR vs GMED

For growth investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Globus Medical, Inc. (GMED) offers the better valuation at 19. 9x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Alphatec Holdings, Inc. (ATEC) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Globus Medical, Inc.

is actually cheaper at 16. 7x.

Over the past 5 years, Globus Medical, Inc.

(GMED) delivered a total return of +9. 7%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: GMED returned +233. 8% versus XTNT's -98. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.

(XTNT) is the lower-risk stock at 0. 67β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 219% more volatile than XTNT relative to the S&P 500. On balance sheet safety, Globus Medical, Inc. (GMED) carries a lower debt/equity ratio of 3% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xtant Medical Holdings, Inc.

(XTNT) is pulling ahead at 28. 4% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to 15. 0% for Alphatec Holdings, Inc.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Globus Medical, Inc.

(GMED) is the more profitable company, earning 18. 3% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMED leads at 16. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Globus Medical, Inc.

(GMED) trades at 16. 7x forward P/E versus 24. 1x for Alphatec Holdings, Inc. — 7. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 162. 1% to $19. 71.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alphatec Holdings, Inc.

(ATEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), +215. 7% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATEC: +215. 7%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ATEC is a small-cap high-growth stock; XTNT is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; GMED is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.